A disease that borrowed its treatments finally gets its own

For as long as dermatomyositis has had a name, it hasn't had a drug designed specifically for it. Doctors treating this rare autoimmune disease have spent decades reaching for medications built for other conditions entirely, oral steroids, immunosuppressants developed for transplant patients, IV immunoglobulin. On Thursday, that changed. The FDA approved Lisraya, known generically as brepocitinib, as the first oral treatment developed and evaluated specifically for dermatomyositis in adults, ending what regulators themselves have described as a genuine gap in care.

Nikolay Nikolov, director of the FDA's Office of Immunology and Inflammation, put the significance plainly in the agency's announcement: "For too long, patients with dermatomyositis have faced a significant unmet need for effective treatments, often relying on therapies meant for other diseases." He called Thursday's approval "a meaningful step forward, giving patients and their healthcare providers an approved oral therapy proven to help manage this rare and debilitating disease."

What dermatomyositis actually does to the body

Dermatomyositis is a systemic autoimmune disease that attacks two systems at once: the muscles and the skin. Patients develop progressive muscle weakness alongside extensive, painful, and intensely itchy skin lesions, and the disease can also raise the risk of interstitial lung disease and, in some patients, certain cancers. Beyond the physical symptoms, the condition takes a heavy toll on daily functioning, disfiguring skin changes, sensitivity to light and touch, and a punishing dependency on high-dose steroids that themselves carry serious long-term side effects. It's a genuinely rare disease, but the absence of a dedicated treatment has made it disproportionately hard to manage well compared with more common autoimmune conditions that already have multiple targeted drugs on the market.

That gap is exactly what made Lisraya's approval carry weight beyond its immediate patient population. Angela Lek, chief research officer at the Muscular Dystrophy Association, welcomed the decision by noting it "represents meaningful progress for the dermatomyositis community and reflects years of scientific innovation, clinical research, and the commitment of people living with the disease who participated in clinical trials."

How the drug actually works

Brepocitinib is a first-in-class dual inhibitor targeting two related enzymes, Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), both part of signaling pathways that immune cells use to coordinate inflammatory attacks. By blocking both simultaneously, the drug suppresses a broad set of cytokines implicated in dermatomyositis, including type I and type II interferon signaling along with interleukin-6, interleukin-12, and interleukin-23. Preclinical research had already shown that type I interferon specifically drives damage to muscle fibers and dermal blood vessels in dermatomyositis, giving researchers a clear mechanistic reason to expect the dual-inhibition approach would translate into real clinical benefit rather than just a theoretically plausible target.

That dual-targeting design distinguishes brepocitinib from earlier JAK inhibitors developed for other autoimmune conditions, including the class of drugs already used to manage joint-focused diseases like rheumatoid arthritis, by specifically addressing the combined skin-and-muscle pathology that makes dermatomyositis distinct from more commonly treated autoimmune disorders.

The trial data behind the approval

The FDA's decision rests on results from VALOR, a Phase 3, randomized, double-blind, placebo-controlled trial that enrolled 241 adults with definite or probable dermatomyositis across 90 sites worldwide, making it the largest clinical trial ever conducted specifically for this disease. Patients were randomized to one of three arms, brepocitinib 30 mg daily, brepocitinib 15 mg daily, or placebo, for 52 weeks, with a protocol-driven steroid taper beginning at week 12.

The higher 30 mg dose delivered a clear result. At week 52, brepocitinib 30 mg produced a 15.3-point greater improvement on the Total Improvement Score, a composite measure capturing muscle strength, skin disease, and physical function, compared with placebo, a difference that was highly statistically significant. That benefit showed up as early as week 4 and held steady through the full year of treatment. The drug also met all nine of its prespecified secondary endpoints, with 68% of patients on the 30 mg dose achieving moderate improvement versus 44% on placebo, and 46% achieving major improvement versus 26% on placebo. The 15 mg dose, by comparison, failed to separate meaningfully from placebo, which is why the approved dose is specifically 30 mg.

Perhaps the most practically significant result concerned steroids. By the end of the study, 55% of patients on brepocitinib had achieved both meaningful disease improvement and minimal or no ongoing steroid use, compared with just 30% on placebo. For a disease where the standard treatment itself, chronic high-dose steroids, carries its own long list of serious side effects, a drug that lets patients meaningfully reduce that steroid burden while still controlling their disease addresses a problem nearly as significant as the underlying condition itself.

What the approval actually changes for patients

Priovant Therapeutics, the Roivant Sciences company that developed brepocitinib, said the drug is available immediately in the United States, with a patient support program that can bring out-of-pocket costs to as little as $0 per month for eligible patients. That immediate availability matters in a therapeutic area where patients have historically had no on-label option at all, only off-label prescriptions of drugs built for other diseases.

The FDA granted brepocitinib both Priority Review and Orphan Drug designations ahead of Thursday's decision, regulatory pathways reserved for treatments addressing serious conditions with limited existing options. That accelerated track record echoes how the FDA moved unusually quickly on Moderna's mRNA flu vaccine for older adults earlier this year, another case where regulators fast-tracked a genuinely novel approach once trial data cleared a high bar. Common side effects reported in the trial included upper respiratory infections, headache, fatigue, and nausea, alongside a boxed warning consistent with other drugs in the JAK inhibitor class, covering risks such as serious infections, blood clots, and certain cancers that regulators require to be disclosed prominently across this entire drug category.

Where this leaves the broader pipeline

Priovant isn't stopping at dermatomyositis. Brepocitinib is already being evaluated in separate Phase 3 programs for non-infectious uveitis and cutaneous sarcoidosis, plus an earlier-stage program for lichen planopilaris, three more conditions where inflammation driven by overlapping cytokine pathways plays a central role. If those trials succeed, Thursday's approval may end up marking the first of several expansions for a drug built around a single, broadly applicable mechanism rather than one narrowly tuned to a single disease.

For now, though, the immediate significance is narrower and more concrete: adults living with dermatomyositis have, for the first time, a medication that was actually designed, tested, and approved for their disease specifically, rather than borrowed from someone else's treatment plan.